Mar 22, 2021 7:00am EDT Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Mar 18, 2021 7:00am EDT Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
Feb 23, 2021 7:00am EST Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference
Jan 21, 2021 7:00am EST Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer
Jan 05, 2021 7:00am EST Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference
Dec 11, 2020 4:01pm EST Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares
Dec 07, 2020 4:00pm EST Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock
Dec 07, 2020 10:00am EST Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting
Dec 03, 2020 4:30pm EST Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer